CA-ENCHROMA
14.12.2022 08:01:37 CET | Business Wire | Press release
The Centre Pompidou today announced that colour blind visitors are now able to borrow EnChroma glasses for colour blindness during visits to the iconic museum. The Centre Pompidou is internationally renowned for its collection of modern and contemporary art totaling over 120,000 works – the most extensive in all of Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213006029/en/
Robert Delaunay, Manège de cochons, 1922. Don de Mme Sonia Delaunay en 1956. Centre Pompidou, Paris, Musée national d’art moderne - Centre de création industrielle. Colour blind view courtesy of EnChroma. (Graphic: Business Wire)
One in twelve men (8%) and one in 200 women (0.5%) are colour blind – about 2.8 million in France, 30 million in Europe and 350 million globally. With over three million annual visitors, an estimated 128,000 guests to the Centre Pompidou are colour blind. EnChroma glasses will enable colour blind visitors to perceive an expanded range of clear, vibrant colour in artwork at the museum for the first time in their lives.
“Always concerned with offering the best visitor experience to all audiences, the Centre Pompidou is delighted to offer people with colour blindness the possibility of trying EnChroma glasses, a very innovative device in the museum sector,” said David Cascaro, Director of the Public Division, Centre Pompidou.
While people with normal colour vision see over one million shades and hues of colour, colour blind people see only an estimated 10% of them. To the red-green colour blind, colours appear dull and washed out, with some difficult to distinguish from each other. Common colour confusions include green and yellow, grey and pink, purple and blue, and red and brown. This can detract from the ability of colour blind people to fully experience colourful art.
"We are thrilled that one of the world’s foremost visionaries in arts and culture – the Centre Pompidou – is demonstrating its commitment to accessibility and inclusion for those with colour vision deficiencies by loaning EnChroma glasses to guests," said Erik Ritchie, CEO of EnChroma. “Their example will generate more awareness for the prevalence and effects of colour blindness, inspire other museums and organizations to follow their lead, and ultimately expand opportunities for colour blind people to more fully experience colorful, iconic artwork like never before.”
The Centre Pompidou is the first museum in France to support the needs of colour blind guests via the EnChroma Colour Accessibility Program™. The program already helps colour blind people at nearly 200 public institutions – including libraries, schools, universities, national parks, gardens, tourism bureaus and 80+ major museums – more fully experience colours in art, nature and overcome obstacles to learning. Other museums participating in the program include the Gallerie d’Italia in Italy, the Chau Chak Wing Museum in Australia, Centraal Museum Utrecht in The Netherlands, and the Georgia O’Keeffe Museum, Dallas Museum of Art, and Crystal Bridges Museum of American Art in the US.
Special optical filters in EnChroma glasses help colour blind people perceive a wider range of colours and see them more vividly and distinctly. A study by the University of California, Davis, and INSERM, the French National Institute for Health and Medical Research, demonstrated the effectiveness of EnChroma glasses. A separate recent study in the scientific publication Eye-Nature also highlights the benefits of the glasses.
EnChroma Colour Accessibility Program™
EnChroma is the leading advocate for accessibility for those with colour blindness. The company donates a pair of glasses for every pair an organization purchases. EnChroma also provides materials for institutions to educate the public or teachers, students and parents about colour blindness and its effects. Public organizations interested in the EnChroma Program can email accessibility@enchroma.com.
About the Centre Pompidou
Since 1977, the Centre Pompidou has been deeply rooted in the city of Paris and open to the world and to innovation. Its iconic building is home to Europe's richest and one of the world's largest collections of modern and contemporary art, in addition to exhibitions, symposiums, festivals, shows, projections, and workshops for young people. Its extremely rich programme at the crossroads of art forms and audiences attracts more than 3.5 million visitors every year. True to its ambition to make culture and creation available to as many people as possible, the Centre Pompidou also develops its regional and international presence. For more information, visit: centrepompidou.fr.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213006029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release
Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 05:49:00 CEST | Press release
Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
